Killing rates exerted by caspofungin in 50% serum and its correlation with in vivo efficacy in a neutropenic murine model against Candida krusei and Candida inconspicua

Journal of Medical Microbiology

Volumn 63, Issue PART 2, 2014, Pages 186-194

  Kovács, Renátó ^a   Gesztelyi, Rudolf ^a   Berényi, Réka ^a   Domán, Marianna ^a   Kardos, Gábor ^a   Juhász, Béla ^a   Majoros, László ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; CYCLOPHOSPHAMIDE; ECHINOCANDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CANDIDA INCONSPICUA; CANDIDA KRUSEI; CANDIDIASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FUNGAL LOAD; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HUMAN; IN VIVO STUDY; LIMIT OF DETECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL;

ANIMALS; CANDIDA; CANDIDIASIS; DISEASE MODELS, ANIMAL; ECHINOCANDINS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84892983226     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.066381-0     Document Type: Article

References (29)

1. Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K. & Lepak, A. (2010). In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54, 2497-2506.
2. Betts, R. F., Nucci, M., Talwar, D., Gareca, M., Queiroz-Telles, F., Bedimo, R. J., Herbrecht, R., Ruiz-Palacios, G., Young, J. A. & other authors (2009). A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48, 1676-1684.
3. Cantón, E., Pemán, J., Valentín, A., Espinel-Ingroff, A. & Gobernado, M. (2009). In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies. Antimicrob Agents Chemother 53, 3108-3111.
4. Cantón, E., Espinel-Ingroff, A., Pemán, J. & Del Castillo, L. (2010). In vitro fungicidal activities of echinocandins against Candida metapsi-losis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob Agents Chemother 54, 2194-2197.
5. Chen, S. C., Slavin, M. A. & Sorrell, T. C. (2011). Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 71, 11-41.
6. Chiller, T., Farrokhshad, K., Brummer, E. & Stevens, D.A. (2000). Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Antimicrob Agents Chemother 44, 3302-3305.
7. CLSI (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard, 3rd edn, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.
8. Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M. (2011). Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 55, 5798-5803.
9. Földi, R., Szilágyi, J., Kardos, G., Berényi, R., Kovács, R. & Majoros, L. (2012). Effect of 50% human serum on the killing activity of micafungin against eight Candida species using time-kill methodology. Diagn Microbiol Infect Dis 73, 338-342.
10. Földi, R., Kovács, R., Gesztelyi, R., Kardos, G., Berényi, R., Juhász, B., Szilágyi, J., Mózes, J. & Majoros, L. (2012). Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans. Mycopathologia 174, 311-318.
11. Garcia-Effron, G. S., Park, S. & Perlin, D.S. (2011). Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin. Antimicrob Agents Chemother 55, 2245-2255.
12. Ishikawa, J., Maeda, T., Matsumura, I., Yasumi, M., Ujiie, H., Masaie, H., Nakazawa, T., Mochizuki, N., Kishino, S. & Kanakura, Y. (2009). Antifungal activity of micafungin in serum. Antimicrob Agents Chemother 53, 4559-4562.
13. Majoros, L., Kardos, G., Belák, Á., Maráz, A., Asztalos, L., Csánky, E., Barta, Z. & Szabó, B. (2003). Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures. J Clin Microbiol 41, 5250-5253.
14. Mukherjee, P. K., Sheehan, D., Puzniak, L., Schlamm, H. & Ghannoum, M. A. (2011). Echinocandins: are they all the same? J Chemother 23, 319-325.
15. Nasar, A., Ryan, L., Frei, C. R., Cota, J. M. & Wiederhold, N. P. (2013). Influence of serum and albumin on echinocandin in vitro potency and pharmacodynamics. Curr Fungal Infect Rep 7, 89-95.
16. Odabasi, Z., Paetznick, V., Rex, J. H. & Ostrosky-Zeichner, L. (2007). Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob Agents Chemother 51, 4214-4216.
17. Paderu, P., Garcia-Effron, G., Balashov, S., Delmas, G., Park, S. & Perlin, D. S. (2007). Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 51, 2253-2256.
18. Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L. & other authors (2007). Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45, 883-893.
19. Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Jr, Calandra, T. F., Edwards, J. E., Jr, Filler, S. G., Fisher, J. F., Kullberg, B. J. (2009). Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48, 503-535.
20. Pfaller, M. A. & Diekema, D. J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133-163.
21. Pfaller, M. A., Diekema, D. J., Andes, D., Arendrup, M. C., Brown, S. D., Lockhart, S. R., Motyl, M., Perlin, D. S. CLSI Subcommittee for Antifungal Testing (2011). Clinical breakpoints for the echino-candins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 14, 164-176.
22. Pfaller, M. A., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H. U., Quan, S. P. & Horn, D. (2012). Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance1) registry, 2004-2008. Diagn Microbiol Infect Dis 74, 323-331.
23. Sirohi, B., Powles, R. L., Chopra, R., Russell, N., Byrne, J. L., Prentice, H. G., Potter, M. & Koblinger, S. (2006). A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 38, 47-51.
24. Spreghini, E., Orlando, F., Tavanti, A., Senesi, S., Giannini, D., Manso, E. & Barchiesi, F. (2012). In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. J Antimicrob Chemother 67, 2195-2202.
25. Szilágyi, J., Földi, R., Bayegan, S., Kardos, G. & Majoros, L. (2012). Effect of nikkomycin Z and 50% human serum on the killing activity of high-concentration caspofungin against Candida species using time-kill methodology. J Chemother 24, 18-25.
26. Szilágyi, J., Földi, R., Gesztelyi, R., Bayegan, S., Kardos, G., Juhász, B. & Majoros, L. (2012). Comparison of the kidney fungal burden in experimental disseminated candidiasis by species of the Candida parapsilosis complex treated with fluconazole, amphotericin B and caspofungin in a temporarily neutropenic murine model. Chemotherapy 58, 159-164.
27. Tortorano, A. M., Prigitano, A., Dho, G., Grancini, A., Passera, M. ECMM-FIMUA Study Group (2012). Antifungal susceptibility profiles of Candida isolates from a prospective survey of invasive fungal infections in Italian intensive care units. J Med Microbiol 61, 389-393.
28. Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M. & Graybill, J. R. (2007). In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob Agents Chemother 51, 1616-1620.
29. Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R. & Patterson, T. F. (2011). Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans. Antimicrob Agents Chemother 55, 3254-3260.